Skip to main
DMRA

DMRA Stock Forecast & Price Target

DMRA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is poised for success with their biologic treatments targeting mutant calreticulin-driven myeloproliferative neoplasms, addressing a crucial medical need in diseases such as essential thrombocythemia and myelofibrosis. With a pipeline of promising products, including DMR-001, DMR-002, and DMR-003, Damora has the potential to significantly improve patient outcomes and capture a considerable share of the $5B+ U.S. market in this space. The company's recent preclinical data presentation at EHA showcases DMR-001's high binding affinity, subtype breadth, and wtCALR sparing, positioning it as a compelling challenger to Incyte's current standard, INCA039989. Furthermore, with a strong portfolio, ample cash reserves, and substantial market potential, Damora is a promising investment opportunity.

Bears say

Damora Therapeutics is a biotechnology company with a promising pipeline of biologics for hematologic disorders. However, the negative outlook is based on several factors. Firstly, the company's lead drug, DMR-001, is still in the preclinical stage and is not expected to begin Phase 3 trials until mid-2028, putting it behind other similar treatments in the market. Additionally, the data for DMR-001's on-target activity and tolerability in human trials still need to be established, and there is no guarantee that it will outperform competing drugs. Finally, Damora's pipeline relies heavily on the success of DMR-001, with its other pipeline products in early stages of development. Without significant revenue from product sales until 2030, the company's financial outlook is not favorable.

DMRA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Damora Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Damora Therapeutics, Inc. (DMRA) Forecast

Analysts have given DMRA a Buy based on their latest research and market trends.

According to 5 analysts, DMRA has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Damora Therapeutics, Inc. (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.